<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29747670</article-id><article-id pub-id-type="pmc">5946494</article-id><article-id pub-id-type="publisher-id">2633</article-id><article-id pub-id-type="doi">10.1186/s13063-018-2633-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The efficacy and safety of <italic>Jiedu Tongluo</italic> granules for treating post-stroke depression with <italic>qi</italic> deficiency and blood stasis syndrome: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Ai-mei</given-names></name><address><email>zhaoaimei@bucm.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Wen-ran</given-names></name><address><email>qwrqwrbs.1@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Li-jun</given-names></name><address><email>mlj0706@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Jun-guo</given-names></name><address><email>reek2003@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Li</given-names></name><address><email>xuli1230@126.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Ming-jiang</given-names></name><address><email>ymj_ren@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bilinksi</surname><given-names>Kellie</given-names></name><address><email>Kellie.Bilinski@bci.org.au</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chang</surname><given-names>Dennis</given-names></name><address><email>d.chang@westernsydney.edu.au</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Jian-xun</given-names></name><address><email>liujx0324@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1431 9176</institution-id><institution-id institution-id-type="GRID">grid.24695.3c</institution-id><institution>Graduate School, Beijing University of Chinese Medicine, </institution></institution-wrap>Beijing, 100029 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0662 3178</institution-id><institution-id institution-id-type="GRID">grid.12527.33</institution-id><institution>Institute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, </institution></institution-wrap>Haidian District, Beijing, 100091 People’s Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.464481.b</institution-id><institution>Department of Neurology, </institution><institution>Xiyuan Hospital of China Academy of Chinese Medical Sciences, </institution></institution-wrap>Beijing, 100091 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9939 5719</institution-id><institution-id institution-id-type="GRID">grid.1029.a</institution-id><institution>NICM, Western Sydney University, </institution></institution-wrap>Locked Bag 1797, Penrith, NSW 2751 Australia </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>19</volume><elocation-id>275</elocation-id><history><date date-type="received"><day>3</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>9</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>© The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="5991" xml_f="6001" txt_i="11" txt_f="21">Background</offsets></title><p id="Par1"><offsets xml_i="6022" xml_f="6458" txt_i="22" txt_f="458">Post-stroke depression (PSD) is the most common psychiatric complication after a stroke. The most frequently used antidepressants are selective serotonin receptor inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), however, these exhibit a series of side effects. Traditional Chinese medicine has been used to treat PSD with few side effects. The aim of this study is to evaluate the efficacy and safety of </offsets><italic><offsets xml_i="6466" xml_f="6479" txt_i="458" txt_f="471">Jiedu Tongluo</offsets></italic><offsets xml_i="6488" xml_f="6520" txt_i="471" txt_f="503"> granules for treating PSD with </offsets><italic><offsets xml_i="6528" xml_f="6541" txt_i="503" txt_f="516">qi deficiency</offsets></italic><offsets xml_i="6550" xml_f="6555" txt_i="516" txt_f="521"> and </offsets><italic><offsets xml_i="6563" xml_f="6584" txt_i="521" txt_f="542">blood stasis syndrome</offsets></italic><offsets xml_i="6593" xml_f="6594" txt_i="542" txt_f="543">.</offsets></p></sec><sec><title><offsets xml_i="6616" xml_f="6623" txt_i="545" txt_f="552">Methods</offsets></title><p id="Par2"><offsets xml_i="6644" xml_f="6844" txt_i="553" txt_f="753">The planned study is a double-blind, randomized, placebo-controlled pilot trial. Eighty participants will be randomly assigned to receive either treatment or placebo. The treatment group will receive </offsets><italic><offsets xml_i="6852" xml_f="6865" txt_i="753" txt_f="766">Jiedu Tongluo</offsets></italic><offsets xml_i="6874" xml_f="7815" txt_i="766" txt_f="1704"> granules (JDTLG) with conventional treatment, and the placebo group will receive placebo with conventional treatment for 8 weeks. The primary outcome is the effectiveness of JDTLG on depression after 8 weeks treatment, which is defined as a decrease of 50% or more in 17-item Hamilton Depression Scale (HAMD-17) score or clinical recovery (score &lt; 7). Secondary outcomes are improvement in neurological function, degree of independence, activities of daily living, and TCM syndrome at each visit, which will be measured with National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index (BI) and TCM scale, respectively. Interleukin (IL)-6, IL-8, and small-molecule metabolites will be monitored to explore the mechanism of action of JDTLG on PSD. Safety measures include vital signs, results of electrocardiography, laboratory index (full blood count, kidney and liver function tests) and adverse events.</offsets></p></sec><sec><title><offsets xml_i="7837" xml_f="7847" txt_i="1706" txt_f="1716">Discussion</offsets></title><p id="Par3"><offsets xml_i="7868" xml_f="7994" txt_i="1717" txt_f="1843">The purpose of this trial is to evaluate the therapeutic effects and safety of JDTLG in individuals with PSD with concomitant </offsets><italic><offsets xml_i="8002" xml_f="8015" txt_i="1843" txt_f="1856">qi deficiency</offsets></italic><offsets xml_i="8024" xml_f="8029" txt_i="1856" txt_f="1861"> and </offsets><italic><offsets xml_i="8037" xml_f="8058" txt_i="1861" txt_f="1882">blood stasis syndrome</offsets></italic><offsets xml_i="8067" xml_f="8166" txt_i="1882" txt_f="1981">. If successful, the outcome of this trial will provide a viable treatment option for PSD patients.</offsets></p></sec><sec><title><offsets xml_i="8188" xml_f="8206" txt_i="1983" txt_f="2001">Trial registration</offsets></title><p id="Par4"><offsets xml_i="8227" xml_f="8250" txt_i="2002" txt_f="2025">ClinicalTrials.gov ID: </offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03147053"><offsets xml_i="8341" xml_f="8352" txt_i="2025" txt_f="2036">NCT03147053</offsets></ext-link><offsets xml_i="8363" xml_f="8394" txt_i="2036" txt_f="2067">. Registered on 27 April 2017. </offsets></p></sec><sec><title><offsets xml_i="8416" xml_f="8449" txt_i="2069" txt_f="2102">Electronic supplementary material</offsets></title><p><offsets xml_i="8460" xml_f="8595" txt_i="2103" txt_f="2238">The online version of this article (10.1186/s13063-018-2633-4) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Jiedu Tongluo</italic> granules</kwd><kwd>Post-stroke depression</kwd><kwd>Randomized controlled trial</kwd><kwd>Chinese herbal medicine</kwd><kwd><italic>Qi</italic> deficiency and blood stasis syndrome</kwd></kwd-group><funding-group><award-group><funding-source><institution>Ministry of Science and Technology of the People's Republic of China (CN)</institution></funding-source><award-id>2015CB554405</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Jian-xun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002855</institution-id><institution>Ministry of Science and Technology of the People's Republic of China</institution></institution-wrap></funding-source><award-id>2012ZX09103201-015</award-id><principal-award-recipient><name><surname>Xu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="9939" xml_f="9949" txt_i="2247" txt_f="2257">Background</offsets></title><p id="Par19"><offsets xml_i="9971" xml_f="10123" txt_i="2258" txt_f="2410">Post-stroke depression (PSD) is one of the most common complications of stroke and is characterized by depressed mood, generalized anxiety, and apathy [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="10155" xml_f="10156" txt_i="2410" txt_f="2411">1</offsets></xref><offsets xml_i="10163" xml_f="10164" txt_i="2411" txt_f="2412">–</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="10196" xml_f="10197" txt_i="2412" txt_f="2413">3</offsets></xref><offsets xml_i="10204" xml_f="10293" txt_i="2413" txt_f="2502">]. The prevalence of PSD is approximately one third of stroke survivors at any one time [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="10325" xml_f="10326" txt_i="2502" txt_f="2503">4</offsets></xref><offsets xml_i="10333" xml_f="10386" txt_i="2503" txt_f="2556">], ranging from 39% to 52% within the first 5 years [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="10418" xml_f="10419" txt_i="2556" txt_f="2557">5</offsets></xref><offsets xml_i="10426" xml_f="10479" txt_i="2557" txt_f="2610">]. PSD patients experience poor functional outcomes [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="10511" xml_f="10512" txt_i="2610" txt_f="2611">6</offsets></xref><offsets xml_i="10519" xml_f="10546" txt_i="2611" txt_f="2638">] and increased mortality [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="10578" xml_f="10579" txt_i="2638" txt_f="2639">7</offsets></xref><offsets xml_i="10586" xml_f="10816" txt_i="2639" txt_f="2869">]. Several therapeutic strategies have been shown to be effective for PSD, including pharmacological, non-pharmacological interventions (e.g., psychotherapy, electroconvulsive therapy, and acupuncture), and combination therapies [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="10848" xml_f="10849" txt_i="2869" txt_f="2870">8</offsets></xref><offsets xml_i="10856" xml_f="11121" txt_i="2870" txt_f="3135">]. The most frequently studied agents are antidepressants, whereby the most thoroughly characterized agents are selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, sertraline, citalopram) and serotonin and norepinephrine reuptake inhibitors (SNRIs) [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="11153" xml_f="11154" txt_i="3135" txt_f="3136">9</offsets></xref><offsets xml_i="11161" xml_f="11298" txt_i="3136" txt_f="3273">]. However, antidepressant medications exhibit a series of side effects, such as increased risk of hemorrhagic complications and stroke [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="11331" xml_f="11333" txt_i="3273" txt_f="3275">10</offsets></xref><offsets xml_i="11340" xml_f="11447" txt_i="3275" txt_f="3382">], although minor side effects such as nausea, diarrhea, fatigue, and dizziness are most commonly reported.</offsets></p><p id="Par20"><offsets xml_i="11465" xml_f="11636" txt_i="3383" txt_f="3554">Traditional Chinese medicine (TCM) has been used to treat PSD and has demonstrated a more favorable safety profile than conventional medicine. A meta-analysis showed that </offsets><italic><offsets xml_i="11644" xml_f="11652" txt_i="3554" txt_f="3562">Liver-qi</offsets></italic><offsets xml_i="11661" xml_f="11780" txt_i="3562" txt_f="3681"> regulation effectively ameliorates depressive symptoms, as well as enhancing quality of life among patients with PSD [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="11813" xml_f="11815" txt_i="3681" txt_f="3683">11</offsets></xref><offsets xml_i="11822" xml_f="11942" txt_i="3683" txt_f="3803">]. According to a data from a previous  research about the syndrome differentiation of ischemic stroke, the syndrome of </offsets><italic><offsets xml_i="11950" xml_f="11964" txt_i="3803" txt_f="3817">“qi deficiency</offsets></italic><offsets xml_i="11973" xml_f="11978" txt_i="3817" txt_f="3822"> and </offsets><italic><offsets xml_i="11986" xml_f="11999" txt_i="3822" txt_f="3835">blood stasis”</offsets></italic><offsets xml_i="12008" xml_f="12127" txt_i="3835" txt_f="3954"> might reach a proportion of 21.54% among the clinical patients, which would rank first within the different subtypes [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="12160" xml_f="12162" txt_i="3954" txt_f="3956">12</offsets></xref><offsets xml_i="12169" xml_f="12321" txt_i="3956" txt_f="4108">]. As a common complication of stroke, PSD can be divided into different syndromes, among which qi deficiency and blood stasis is an important subtype [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="12354" xml_f="12356" txt_i="4108" txt_f="4110">13</offsets></xref><offsets xml_i="12363" xml_f="12365" txt_i="4110" txt_f="4112">, </offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="12398" xml_f="12400" txt_i="4112" txt_f="4114">14</offsets></xref><offsets xml_i="12407" xml_f="12410" txt_i="4114" txt_f="4117">]. </offsets><italic><offsets xml_i="12418" xml_f="12431" txt_i="4117" txt_f="4130">Jiedu Tongluo</offsets></italic><offsets xml_i="12440" xml_f="12571" txt_i="4130" txt_f="4261"> granules (JDTLG) is a patented complex Chinese medicine formulation (No: 201510419571.3), which consist of seven herbs, including </offsets><italic><offsets xml_i="12579" xml_f="12592" txt_i="4261" txt_f="4274">Panax ginseng</offsets></italic><offsets xml_i="12601" xml_f="12603" txt_i="4274" txt_f="4276"> (</offsets><italic><offsets xml_i="12611" xml_f="12619" txt_i="4276" txt_f="4284">Ren Shen</offsets></italic><offsets xml_i="12628" xml_f="12644" txt_i="4284" txt_f="4300">) 12.5 g/100 g, </offsets><italic><offsets xml_i="12652" xml_f="12665" txt_i="4300" txt_f="4313">Ginkgo biloba</offsets></italic><offsets xml_i="12674" xml_f="12676" txt_i="4313" txt_f="4315"> (</offsets><italic><offsets xml_i="12684" xml_f="12695" txt_i="4315" txt_f="4326">Yin Xing Ye</offsets></italic><offsets xml_i="12704" xml_f="12718" txt_i="4326" txt_f="4340">) 25 g/100 g, </offsets><italic><offsets xml_i="12726" xml_f="12749" txt_i="4340" txt_f="4363">Hypericum perforatum L.</offsets></italic><offsets xml_i="12758" xml_f="12760" txt_i="4363" txt_f="4365"> (</offsets><italic><offsets xml_i="12768" xml_f="12785" txt_i="4365" txt_f="4382">Guan Ye Lian Qiao</offsets></italic><offsets xml_i="12794" xml_f="12810" txt_i="4382" txt_f="4398">) 12.5 g/100 g, </offsets><italic><offsets xml_i="12818" xml_f="12848" txt_i="4398" txt_f="4428">Scutellaria baicalensis Georgi</offsets></italic><offsets xml_i="12857" xml_f="12859" txt_i="4428" txt_f="4430"> (</offsets><italic><offsets xml_i="12867" xml_f="12876" txt_i="4430" txt_f="4439">Huang Qin</offsets></italic><offsets xml_i="12885" xml_f="12901" txt_i="4439" txt_f="4455">) 12.5 g/100 g, </offsets><italic><offsets xml_i="12909" xml_f="12935" txt_i="4455" txt_f="4481">Gardenia jasminoides Ellis</offsets></italic><offsets xml_i="12944" xml_f="12946" txt_i="4481" txt_f="4483"> (</offsets><italic><offsets xml_i="12954" xml_f="12960" txt_i="4483" txt_f="4489">Zhi Zi</offsets></italic><offsets xml_i="12969" xml_f="12985" txt_i="4489" txt_f="4505">) 12.5 g/100 g, </offsets><italic><offsets xml_i="12993" xml_f="13012" txt_i="4505" txt_f="4524">Gastrodia elata Bl.</offsets></italic><offsets xml_i="13021" xml_f="13023" txt_i="4524" txt_f="4526"> (</offsets><italic><offsets xml_i="13031" xml_f="13038" txt_i="4526" txt_f="4533">Tian Ma</offsets></italic><offsets xml_i="13047" xml_f="13067" txt_i="4533" txt_f="4553">) 12.5 g/100 g, and </offsets><italic><offsets xml_i="13075" xml_f="13101" txt_i="4553" txt_f="4579">Ligusticum chuanxiong hort</offsets></italic><offsets xml_i="13110" xml_f="13112" txt_i="4579" txt_f="4581"> (</offsets><italic><offsets xml_i="13120" xml_f="13131" txt_i="4581" txt_f="4592">Chuan Xiong</offsets></italic><offsets xml_i="13140" xml_f="13224" txt_i="4592" txt_f="4676">) 12.5 g/100 g. According to the TCM theory, these herbs are believed to supplement </offsets><italic><offsets xml_i="13232" xml_f="13234" txt_i="4676" txt_f="4678">qi</offsets></italic><offsets xml_i="13243" xml_f="13325" txt_i="4678" txt_f="4760"> and activate blood circulation, remove toxins and relieve stagnation, extinguish </offsets><italic><offsets xml_i="13333" xml_f="13337" txt_i="4760" txt_f="4764">wind</offsets></italic><offsets xml_i="13346" xml_f="13482" txt_i="4764" txt_f="4900">, and dredge collaterals. One previous study showed that JDTLG significantly improved depression-like behavior in animal stroke models [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="13515" xml_f="13517" txt_i="4900" txt_f="4902">15</offsets></xref><offsets xml_i="13524" xml_f="13527" txt_i="4902" txt_f="4905">]. </offsets><italic><offsets xml_i="13535" xml_f="13548" txt_i="4905" txt_f="4918">Panax ginseng</offsets></italic><offsets xml_i="13557" xml_f="13562" txt_i="4918" txt_f="4923"> and </offsets><italic><offsets xml_i="13570" xml_f="13583" txt_i="4923" txt_f="4936">Ginkgo biloba</offsets></italic><offsets xml_i="13592" xml_f="13666" txt_i="4936" txt_f="5010">, key components of JDTLG, are known to possess neuro-protective effects [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="13699" xml_f="13701" txt_i="5010" txt_f="5012">16</offsets></xref><offsets xml_i="13708" xml_f="13709" txt_i="5012" txt_f="5013">–</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="13742" xml_f="13744" txt_i="5013" txt_f="5015">20</offsets></xref><offsets xml_i="13751" xml_f="13765" txt_i="5015" txt_f="5029">]. Furthermore</offsets><italic><offsets xml_i="13773" xml_f="13818" txt_i="5029" txt_f="5074">, the antidepressant effects of Panax ginseng</offsets></italic><offsets xml_i="13827" xml_f="13829" txt_i="5074" txt_f="5076"> [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="13862" xml_f="13864" txt_i="5076" txt_f="5078">21</offsets></xref><offsets xml_i="13871" xml_f="13877" txt_i="5078" txt_f="5084">] and </offsets><italic><offsets xml_i="13885" xml_f="13898" txt_i="5084" txt_f="5097">Ginkgo biloba</offsets></italic><offsets xml_i="13907" xml_f="13911" txt_i="5097" txt_f="5101">’s [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="13944" xml_f="13946" txt_i="5101" txt_f="5103">22</offsets></xref><offsets xml_i="13953" xml_f="14647" txt_i="5103" txt_f="5797">] might be derived from activation of the signaling pathway involving brain derived neurotrophic factor (BDNF). Our preclinical pharmacological experiments have shown that JDTLG has a neuroprotective and anti-apoptotic effect via up-regulating the expression of BDNF, hypoxia-inducible factor 1-alpha (HIF1α), cAMP-response element binding protein (CREB) and reducing the expression of vascular cell adhesion molecule1 (VCAM1) and matrix metallopeptidase 9 (MMP9). In addition, JDTLG can exert an anti-depressant function through increasing the expression of tropomyosin receptor kinase B (TrkB), mammalian target of rapamycin (mTOR), and 5-hydroxytryptamine (5-HT) receptor (unpublished data).</offsets></p><p id="Par21"><offsets xml_i="14665" xml_f="14833" txt_i="5798" txt_f="5966">This study aims to explore whether JDTLG can improve depression and daily living compared with placebo in PSD participants with qi deficiency and blood stasis syndrome.</offsets></p></sec><sec id="Sec2"><title><offsets xml_i="14865" xml_f="14879" txt_i="5968" txt_f="5982">Methods/design</offsets></title><sec id="Sec3"><title><offsets xml_i="14909" xml_f="14921" txt_i="5983" txt_f="5995">Study design</offsets></title><p id="Par22"><offsets xml_i="14943" xml_f="15715" txt_i="5996" txt_f="6768">This is a double-blind, randomized, placebo-controlled, pilot trial designed to evaluate the safety and efficacy of JDTLG in treating PSD with qi deficiency and blood stasis syndrome. Eighty participants with PSD will be recruited from Xiyuan Hospital of China Academy of Chinese Medical Sciences. After obtaining written informed consent from participants or their legal guardian, participants will be randomly assigned to either the treatment or placebo group with a ratio of 1:1. Participants will undergo an 8-week treatment period and an 8-week follow up. The protocol design is based on the Consolidated Standards of Reporting Trials (CONSORT) guidelines and Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist (see Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="15751" xml_f="15752" txt_i="6768" txt_f="6769">1</offsets></xref><offsets xml_i="15759" xml_f="15761" txt_i="6769" txt_f="6771">).</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="15793" xml_f="15804" txt_i="6773" txt_f="6784">Recruitment</offsets></title><p id="Par23"><offsets xml_i="15826" xml_f="16540" txt_i="6785" txt_f="7499">Participants will be recruited by Internet advertisement and posters in the community and selected hospitals. Potential participants will be assessed by an attending trial physician who will determine whether the participant meets the eligibility criteria. The physician will explain the study’s aims, procedures, and possible side effects of participation in detail and provide the participant with a copy of the Participant Information Sheet. The recruitment started in April 2017 and is estimated to end in March 2018. If the potential participant is eligible and interested in participating, they will be invited for a baseline screening prior to randomization. An outline of procedures is illustrated in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="16572" xml_f="16573" txt_i="7499" txt_f="7500">1</offsets></xref><offsets xml_i="16580" xml_f="16581" txt_i="7500" txt_f="7501">.</offsets><fig id="Fig1"><label><offsets xml_i="16603" xml_f="16609" txt_i="7501" txt_f="7507">Fig. 1</offsets></label><caption><p><offsets xml_i="16629" xml_f="16642" txt_i="7507" txt_f="7520">Study outline</offsets></p></caption><graphic xlink:href="13063_2018_2633_Fig1_HTML" id="MO1"></graphic></fig></p></sec><sec id="Sec5"><title><offsets xml_i="16761" xml_f="16780" txt_i="7523" txt_f="7542">Diagnostic criteria</offsets></title><p id="Par24"><offsets xml_i="16802" xml_f="16857" txt_i="7543" txt_f="7598">A diagnosis of stroke will be established according to </offsets><italic><offsets xml_i="16865" xml_f="16918" txt_i="7598" txt_f="7651">all kinds of cerebrovascular disease diagnosis points</offsets></italic><offsets xml_i="16927" xml_f="16929" txt_i="7651" txt_f="7653"> [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="16962" xml_f="16964" txt_i="7653" txt_f="7655">23</offsets></xref><offsets xml_i="16971" xml_f="17023" txt_i="7655" txt_f="7707">]. Clinical diagnosis of depression is based on the </offsets><italic><offsets xml_i="17031" xml_f="17099" txt_i="7707" txt_f="7775">Chinese Classification and Diagnostic Criteria of Mental Disorders-3</offsets></italic><offsets xml_i="17108" xml_f="17119" txt_i="7775" txt_f="7786"> (CCMD-3) [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="17152" xml_f="17154" txt_i="7786" txt_f="7788">24</offsets></xref><offsets xml_i="17161" xml_f="17171" txt_i="7788" txt_f="7798">] and the </offsets><italic><offsets xml_i="17179" xml_f="17235" txt_i="7798" txt_f="7854">Diagnostic and Statistical Manual of Mental Disorders-IV</offsets></italic><offsets xml_i="17244" xml_f="17331" txt_i="7854" txt_f="7941"> (DSM-IV). The TCM syndrome of qi deficiency and blood stasis in the study follows the </offsets><italic><offsets xml_i="17339" xml_f="17395" txt_i="7941" txt_f="7997">Guidelines for Clinical Research of New Chinese Medicine</offsets></italic><offsets xml_i="17404" xml_f="17406" txt_i="7997" txt_f="7999"> [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="17439" xml_f="17441" txt_i="7999" txt_f="8001">25</offsets></xref><offsets xml_i="17448" xml_f="17449" txt_i="8001" txt_f="8002">]</offsets><italic><offsets xml_i="17457" xml_f="17458" txt_i="8002" txt_f="8003">.</offsets></italic><offsets xml_i="17467" xml_f="17508" txt_i="8003" txt_f="8044"> The diagnostic standards are as follows:</offsets><list list-type="order"><list-item><p id="Par25"><offsets xml_i="17557" xml_f="17732" txt_i="8044" txt_f="8219">Primary signs and symptoms include hemiplegia, tongue skew, tongue strong with no words, partial numbness or feeling diminished or disappeared, emotional depression or anxiety</offsets></p></list-item><list-item><p id="Par26"><offsets xml_i="17773" xml_f="17914" txt_i="8220" txt_f="8361">Secondary signs and symptoms include dizziness, shortness of breath, dark lips, and pale tongue with petechial ecchymosis, string slide pulse</offsets></p></list-item></list></p><p id="Par27"><offsets xml_i="17955" xml_f="18200" txt_i="8363" txt_f="8608">In the diagnosis of stroke involving both collateral and meridian, participants will be diagnosed with qi deficiency and blood stasis syndrome under condition of two or more primary signs/symptoms, as well as at least two primary signs/symptoms.</offsets></p><sec id="Sec6"><title><offsets xml_i="18226" xml_f="18244" txt_i="8609" txt_f="8627">Inclusion criteria</offsets></title><p id="Par28"><offsets xml_i="18266" xml_f="18267" txt_i="8628" txt_f="8629">
</offsets><list list-type="order"><list-item><p id="Par29"><offsets xml_i="18316" xml_f="18386" txt_i="8629" txt_f="8699">Clinical diagnosis of stroke, showing symptoms of neurological deficit</offsets></p></list-item><list-item><p id="Par30"><offsets xml_i="18427" xml_f="18493" txt_i="8700" txt_f="8766">Clinical diagnosis of depression according to the DSM-IV or CCMD-3</offsets></p></list-item><list-item><p id="Par31"><offsets xml_i="18534" xml_f="18597" txt_i="8767" txt_f="8830">A score of 7–24 on the 17-item Hamilton Depression rating scale</offsets></p></list-item><list-item><p id="Par32"><offsets xml_i="18638" xml_f="18721" txt_i="8831" txt_f="8914">Absence of psychiatric disease history or family history of psychosis before stroke</offsets></p></list-item><list-item><p id="Par33"><offsets xml_i="18762" xml_f="18856" txt_i="8915" txt_f="9009">Conscious and cooperative, without aphasia or severe cognitive impairment 2 weeks after stroke</offsets></p></list-item><list-item><p id="Par34"><offsets xml_i="18897" xml_f="18971" txt_i="9010" txt_f="9084">Hormones or psychotropic drugs not used within 1 month prior to enrollment</offsets></p></list-item><list-item><p id="Par35"><offsets xml_i="19012" xml_f="19049" txt_i="9085" txt_f="9122">Normal liver and renal function tests</offsets></p></list-item><list-item><p id="Par36"><offsets xml_i="19090" xml_f="19110" txt_i="9123" txt_f="9143">Aged 45–80 years old</offsets></p></list-item><list-item><p id="Par37"><offsets xml_i="19151" xml_f="19238" txt_i="9144" txt_f="9231">Diagnosis of qi deficiency and blood stasis syndrome according to TCM pattern diagnosis</offsets></p></list-item><list-item><p id="Par38"><offsets xml_i="19279" xml_f="19328" txt_i="9232" txt_f="9281">Able to provide voluntary signed informed consent</offsets></p></list-item></list><offsets xml_i="19351" xml_f="19352" txt_i="9282" txt_f="9283">
</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="19384" xml_f="19402" txt_i="9285" txt_f="9303">Exclusion criteria</offsets></title><p id="Par39"><offsets xml_i="19424" xml_f="19425" txt_i="9304" txt_f="9305">
</offsets><list list-type="order"><list-item><p id="Par40"><offsets xml_i="19474" xml_f="19536" txt_i="9305" txt_f="9367">Suspected secondary stroke caused by brain tumor, brain trauma</offsets></p></list-item><list-item><p id="Par41"><offsets xml_i="19577" xml_f="19822" txt_i="9368" txt_f="9613">Unstable vital signs, or presence of severe primary hepatic or renal insufficiency (defined as the alanine aminotransferase (ALT), or the aspartate aminotransferase (AST), the serum creatinine concentration value twice of the normal upper limit)</offsets></p></list-item><list-item><p id="Par42"><offsets xml_i="19863" xml_f="19939" txt_i="9614" txt_f="9690">Presence of other chronic disorders (e.g., chronic alcoholism or drug abuse)</offsets></p></list-item><list-item><p id="Par43"><offsets xml_i="19980" xml_f="20073" txt_i="9691" txt_f="9784">Poorly controlled diabetes (the preprandial blood glucose is twice the upper limit of normal)</offsets></p></list-item><list-item><p id="Par44"><offsets xml_i="20114" xml_f="20150" txt_i="9785" txt_f="9821">Currently pregnant or breast-feeding</offsets></p></list-item><list-item><p id="Par45"><offsets xml_i="20191" xml_f="20226" txt_i="9822" txt_f="9857">Allergy to the ingredients in JDTLG</offsets></p></list-item><list-item><p id="Par46"><offsets xml_i="20267" xml_f="20316" txt_i="9858" txt_f="9907">Currently participating in another clinical trial</offsets></p></list-item></list><offsets xml_i="20339" xml_f="20340" txt_i="9908" txt_f="9909">
</offsets></p></sec></sec><sec id="Sec8"><title><offsets xml_i="20378" xml_f="20408" txt_i="9912" txt_f="9942">Withdrawal and discontinuation</offsets></title><p id="Par47"><offsets xml_i="20430" xml_f="21406" txt_i="9943" txt_f="10919">Participants are able to voluntarily withdraw at any time during the trial. Participants who fail to complete the study, regardless of time or reason, will be considered as dropouts. The last recorded data for these participants will be included in data analyses. Data obtained from participants who experience unrelated complications, such as substantial change in disease status, exacerbation of depression or commence medication that could potentially interfere with JDTLG, will be treated as invalid. Withdrawal due to adverse events will be distinguished from withdrawal due to insufficient response. All adverse effects will be analyzed at the endpoint of the trial regardless of whether they are deemed related to the trial medication or not. If a participant withdraws due to a serious adverse event, it will be reported in accordance with the reporting requirements. Where appropriate, data collected by these participants will be used in intention-to-treat analyses.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="21438" xml_f="21450" txt_i="10921" txt_f="10933">Intervention</offsets></title><p id="Par48"><offsets xml_i="21472" xml_f="22714" txt_i="10934" txt_f="12176">Participants will be allocated to receive JDTLG or placebo for 8 weeks in addition to their usual conventional treatment (e.g., antiplatelet, lipid-lowering, antihypertensive, or antidiabetic therapy). The JDTLG and placebo granules (3.9 g/sachet) will be taken orally with warm water twice a day for 8 weeks. Product will be provided by China Resources Sanjiu Medical and Pharmaceutical Co., Ltd., Shenzhen, China (Production batch number: 161001 W). Analyses have shown that the quality of JDTLG is consistent with the Chinese Medicine Standards of the State Food and Drug Administration (SFDA). Active granules contain 3.9 g of JDTLG each, which is equivalent to 24 g of crude medicine. Placebo granules are composed of 10% crude JDTLG and 90% starch and are of identical appearance and smell as the active granules. Participants will be instructed to refrain from all other Chinese herbal decoctions or medicines used to treat PSD during the study. Participants can withdraw from the study and choose modern medical treatments, such as SSRI antidepressants, when their depressive symptoms worsen. All of the unused granules will be asked to be returned to the trial team and reasons of not taking the medicine will be recorded on the CRF.</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="22747" xml_f="22768" txt_i="12178" txt_f="12199">Outcomes and measures</offsets></title><sec id="Sec11"><title><offsets xml_i="22799" xml_f="22814" txt_i="12200" txt_f="12215">Primary outcome</offsets></title><p id="Par49"><offsets xml_i="22836" xml_f="23077" txt_i="12216" txt_f="12454">The primary outcome is the effectiveness of JDTLG on reducing depression after 8 weeks of treatment. Efficacy defined as a decrease of 50% or more in the 17-item Hamilton Depression Scale (HAMD-17) score or clinical recovery (score &lt; 7) [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="23110" xml_f="23112" txt_i="12454" txt_f="12456">26</offsets></xref><offsets xml_i="23119" xml_f="23121" txt_i="12456" txt_f="12458">].</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="23154" xml_f="23172" txt_i="12460" txt_f="12478">Secondary outcomes</offsets></title><p id="Par50"><offsets xml_i="23194" xml_f="23195" txt_i="12479" txt_f="12480">
</offsets><list list-type="bullet"><list-item><p id="Par51"><offsets xml_i="23245" xml_f="23569" txt_i="12480" txt_f="12804">Improvement in neurological function at each appointment throughout the trial. Efficacy will be determined by a reduction of ≥ 50% or the total score of 0–1 in the 15-item National Institute of Health Stroke Scale (NIHSS) score (scores range from 0 to 42, whereby higher scores indicate a more severe neurological deficit) [</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="23602" xml_f="23604" txt_i="12804" txt_f="12806">27</offsets></xref><offsets xml_i="23611" xml_f="23612" txt_i="12806" txt_f="12807">]</offsets></p></list-item><list-item><p id="Par52"><offsets xml_i="23653" xml_f="23883" txt_i="12808" txt_f="13038">The improvement in independence at each appointment as measured by a modified Rankin Scale (mRS) at each appointment throughout the trial (scores on this scale range from 0 to 6, with higher scores indicating greater disability) [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="23916" xml_f="23918" txt_i="13038" txt_f="13040">28</offsets></xref><offsets xml_i="23925" xml_f="23926" txt_i="13040" txt_f="13041">]</offsets></p></list-item><list-item><p id="Par53"><offsets xml_i="23967" xml_f="24217" txt_i="13042" txt_f="13292">The proportion of participants with a Barthel Index (BI) score of ≥ 90 at each appointment throughout the trial. The BI is used to evaluate the activities of daily living, ranging from 0 to 100, whereby higher scores indicate increased independence [</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="24250" xml_f="24252" txt_i="13292" txt_f="13294">29</offsets></xref><offsets xml_i="24259" xml_f="24260" txt_i="13294" txt_f="13295">]</offsets></p></list-item><list-item><p id="Par54"><offsets xml_i="24301" xml_f="24631" txt_i="13296" txt_f="13620">The improvement of TCM syndrome at each appointment as measured by the reduction (reduction = (before treatment score − after treatment score)/before treatment score × 100%) in the following scale: clinical cure: reduction &gt; 75%, markedly effective: reduction 51–75%, effective: reduction 25– 50%, invalid: reduction &lt; 25% [</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="24664" xml_f="24666" txt_i="13620" txt_f="13622">30</offsets></xref><offsets xml_i="24673" xml_f="24674" txt_i="13622" txt_f="13623">]</offsets></p></list-item></list><offsets xml_i="24697" xml_f="24698" txt_i="13624" txt_f="13625">
</offsets></p></sec><sec id="Sec13"><title><offsets xml_i="24731" xml_f="24751" txt_i="13627" txt_f="13647">Exploratory outcomes</offsets></title><p id="Par55"><offsets xml_i="24773" xml_f="24954" txt_i="13648" txt_f="13829">Interleukin (IL)-6, IL-8, and small-molecule metabolites will be monitored to explore the mechanism of PSD at baseline and weeks 4 and 8. Serum inflammatory cytokines such as IL-6 [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="24987" xml_f="24989" txt_i="13829" txt_f="13831">31</offsets></xref><offsets xml_i="24996" xml_f="25008" txt_i="13831" txt_f="13843">] and IL-8 [</offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="25041" xml_f="25043" txt_i="13843" txt_f="13845">32</offsets></xref><offsets xml_i="25050" xml_f="25256" txt_i="13845" txt_f="14051">], which are shown to participate in the pathological processes of both stroke and depression and provide some prediction values, will be detected using enzyme-linked immunosorbent assay (ELISA) techniques.</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="25289" xml_f="25304" txt_i="14053" txt_f="14068">Safety measures</offsets></title><p id="Par56"><offsets xml_i="25326" xml_f="25669" txt_i="14069" txt_f="14412">Safety measures will include vital signs, results of electrocardiography, a complete blood count, kidney and liver function tests (include blood lipid panel: total cholesterol, triglycerides, high-and low-density lipoproteins). All adverse events will be followed from the time of randomization to up to 16 weeks after the end of intervention.</offsets></p></sec></sec><sec id="Sec15"><title><offsets xml_i="25708" xml_f="25725" txt_i="14415" txt_f="14432">Safety assessment</offsets></title><p id="Par57"><offsets xml_i="25747" xml_f="26364" txt_i="14433" txt_f="15050">Safety evaluation will be based on the incidence of adverse events (AEs) including clinically significant changes identified during physical examinations, vital signs (temperature, blood pressure, breathing and heart rate), and standard clinical laboratory tests (complete blood count, liver and renal function tests). Participants will be asked to report any abnormal events occurring at any time during the trial to the investigators. All details of related and unexpected AEs will be recorded on Case Report Forms (CRF). Safety will be monitored every 4 weeks, and for up to 16 weeks after the end of intervention.</offsets></p></sec><sec id="Sec16"><title><offsets xml_i="26397" xml_f="26424" txt_i="15052" txt_f="15079">Study visits and procedures</offsets></title><p id="Par58"><offsets xml_i="26446" xml_f="26594" txt_i="15080" txt_f="15228">The visit schedule for all evaluations (baseline, primary outcomes, secondary outcomes, exploring outcomes and safety indicators) is shown in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="26628" xml_f="26629" txt_i="15228" txt_f="15229">1</offsets></xref><offsets xml_i="26636" xml_f="27104" txt_i="15229" txt_f="15697">. Participants will be assessed by the same investigator at each assessment. Baseline measurements, demographic characteristics, and medical history will be collected at the first visit only. All concomitant medications will be recorded during the treatment period (i.e., baseline to 8 weeks), including the name, dosage, and course of these medications. Primary and secondary outcomes and safety indicators will be collected every 4 weeks from baseline until week 16.</offsets><table-wrap id="Tab1"><label><offsets xml_i="27133" xml_f="27140" txt_i="15697" txt_f="15704">Table 1</offsets></label><caption><p><offsets xml_i="27160" xml_f="27204" txt_i="15704" txt_f="15748">Measurement items and points of data capture</offsets></p></caption><graphic xlink:href="13063_2018_2633_Tab1_HTML" id="MO3"></graphic><table-wrap-foot><p><offsets xml_i="27305" xml_f="27657" txt_i="15749" txt_f="16101">Abbreviations: CT Computed Tomography, MRI Magnetic Resonance Imaging, ECG electrocardiogram, IL interleukin, TC total cholesterol, TG triglycerides, LDL low density lipoprotein, HDL high density lipoprotein, HAMD-17 17-item Hamilton Depression Scale, BI Barthel Index, NIHSS National Institute of Health stroke scale, TCM traditional Chinese medicine.</offsets></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec17"><title><offsets xml_i="27725" xml_f="27751" txt_i="16104" txt_f="16130">Randomization and blinding</offsets></title><p id="Par59"><offsets xml_i="27773" xml_f="28500" txt_i="16131" txt_f="16858">A statistician from Xiyuan Hospital GCP Center will generate the randomization code. Eighty participants will be assigned to one of two groups at the ratio of 1:1, whereby the treatment and placebo groups will be coded A and B, respectively. The code will be placed in an envelope and subsequently sealed. The statistician will send the envelope directly to the product manufacturer for labeling of the active and placebo product according to the randomization code. All participants and attending physicians will be blinded to treatment assignment until study completion. Duplicated blinding codes will be given to the research institution and the manufacturer and will not be broken during the trial unless required to do so.</offsets></p></sec><sec id="Sec18"><title><offsets xml_i="28533" xml_f="28568" txt_i="16860" txt_f="16895">Data management and quality control</offsets></title><p id="Par60"><offsets xml_i="28590" xml_f="28805" txt_i="16896" txt_f="17111">The trial will be conducted according to the ICH Guidelines for Good Clinical Practice in effort to guarantee the rigor of the study. Data will be imported in the clinical data management system (CDMS) available at </offsets><ext-link ext-link-type="uri" xlink:href="http://www.xyedc.com"><offsets xml_i="28869" xml_f="28889" txt_i="17111" txt_f="17131">http://www.xyedc.com</offsets></ext-link><offsets xml_i="28900" xml_f="29724" txt_i="17131" txt_f="17955">, and an independent organization will be responsible for the data management. The investigators are required to attend a series of training sessions which will cover correct administration of the assessments, participant instruction procedures regarding the use of study granules, collection of study variables, CRF completion, and use of the CDMS. Data is to be imported into the CDMS by two independent researchers within 1 week of collection. All discrepant entries will be marked and recorded for resolution at the clinical data system. After the first participant has completed, regular visits will be performed by an independent trial monitor who has been appointed by the trial sponsor. The monitor will review the two entries, resolve discrepancies, and recheck the CRFs and investigators’ source data if necessary.</offsets></p></sec><sec id="Sec19"><title><offsets xml_i="29757" xml_f="29781" txt_i="17957" txt_f="17981">Compliance and retention</offsets></title><p id="Par61"><offsets xml_i="29803" xml_f="30743" txt_i="17982" txt_f="18922">In order to maximize compliance and retention throughout the study, we will ensure the study schedule and requirements of participation are fully explained prior to obtaining consent, and that participants are aware of the potential risks and benefits of treatment. A copy of the signed informed consent form, containing the contact details of investigators, will be given to each participant so that they are able to contact the principal investigator if required. What is more, all participants will receive a telephone call before each follow-up appointment to remind them of the treatment time and location. Additionally, 8 weeks of medication will be given to participants in two separate sessions to avoid it being misplaced; i.e., at baseline and at week 4. We will try to prevent dropouts by providing ongoing support to participants. Transport allowance, free medical and relative examination will be provided for the participants.</offsets></p></sec><sec id="Sec20"><title><offsets xml_i="30776" xml_f="30799" txt_i="18924" txt_f="18947">Sample size calculation</offsets></title><p id="Par62"><offsets xml_i="30821" xml_f="31173" txt_i="18948" txt_f="19300">This is an exploratory clinical trial designed to provide scientific rationale and feasibility for clinical phase II pilot study and, therefore, is not fully powered. A sample size of 80 participants will be recruited, with 40 participants in each treatment group. Results from this study will be used to for sample size calculations in future studies.</offsets></p></sec><sec id="Sec21"><title><offsets xml_i="31206" xml_f="31226" txt_i="19302" txt_f="19322">Statistical analysis</offsets></title><p id="Par63"><offsets xml_i="31248" xml_f="31417" txt_i="19323" txt_f="19492">All of the data from this study will be analyzed by biostatisticians using SPSS 20.0 (IBM Corp., Armonk, NY, USA). Outcomes are based on the intention-to-treat analysis.</offsets></p><p id="Par64"><offsets xml_i="31435" xml_f="31616" txt_i="19493" txt_f="19674">Baseline characteristics will be summarized by means of simple descriptive statistics and be compared between two study groups to assess covariate balance. The two-sample Student’s </offsets><italic><offsets xml_i="31624" xml_f="31625" txt_i="19674" txt_f="19675">t</offsets></italic><offsets xml_i="31634" xml_f="31758" txt_i="19675" txt_f="19799"> test will be used for continuous variables and the chi-square test or Wilcoxon test will be used for categorical variables.</offsets></p><p id="Par65"></p><p id="Par66"><offsets xml_i="31794" xml_f="32367" txt_i="19801" txt_f="20374">Secondary analyses will include the improved cases in neurological function (NIHSS score reduction of ≥ 50% or the total score of 0–1), independence (mRS 0, 1, and 2), daily living (BI scores ≥ 90), and TCM syndrome. Secondary outcome analyses will be carried out according to standard statistical principles for comparison of parametric or non-parametric distributions as appropriate. Logistical regression analysis will be used to adjust for chance imbalances in the main prognostic variables between groups, such as age, NIHSS scores, BI scores, and TCM syndrome scores.</offsets></p></sec></sec><sec id="Sec22"><title><offsets xml_i="32406" xml_f="32416" txt_i="20377" txt_f="20387">Discussion</offsets></title><p id="Par67"><offsets xml_i="32438" xml_f="32539" txt_i="20388" txt_f="20489">Depression is common after stroke and is related to with poor functional outcome and high mortality [</offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="32572" xml_f="32574" txt_i="20489" txt_f="20491">33</offsets></xref><offsets xml_i="32581" xml_f="32797" txt_i="20491" txt_f="20707">]. The association between depression and stroke has been established whereby stroke has been shown to increase the risk of PSD, and conversely, depression has been shown to be an independent risk factor for stroke [</offsets><xref ref-type="bibr" rid="CR34"><offsets xml_i="32830" xml_f="32832" txt_i="20707" txt_f="20709">34</offsets></xref><offsets xml_i="32839" xml_f="33339" txt_i="20709" txt_f="21209">]. The most commonly used antidepressants are SSRI and SNRIs, although they are not without side effects including increasing risk of hemorrhagic complications. As antidepressant medications have the potential to cause a series of adverse effects and are associated with poor patient compliance, it is important to explore other effective treatments that may have fewer side effects in the management of PSD. Chinese herbal medicine has the potential to offer an effective and safe treatment for PSD.</offsets></p><p id="Par68"><offsets xml_i="33357" xml_f="33780" txt_i="21210" txt_f="21633">In this trial, we will investigate whether the JDTLG plus conventional treatment can reduce depression and improve daily living ability among participants who have recently suffered a stroke. We have previously shown that JDTLG effectively treats PSD in a rat model. This study will be conducted as a randomized, double-blind, placebo-controlled pilot crossover trial to provide evidence for the clinical efficacy of JDTLG.</offsets></p><p id="Par69"><offsets xml_i="33798" xml_f="34261" txt_i="21634" txt_f="22097">The purpose of this prospective trial is to prove the therapeutic efficacy and safety of JDTLG. The outcome of the trial will provide evidence-based data regarding whether JDTLG is beneficial for PSD participants with qi deficiency and blood stasis syndrome. More importantly, the success of this study will support a large-scale clinical study to further consolidate the evidence for the use of JDTLG in PSD patients with qi deficiency and blood stasis syndrome.</offsets></p><p id="Par70"><offsets xml_i="34279" xml_f="34710" txt_i="22098" txt_f="22529">This study has several limitations that require consideration. Firstly, as the study is being undertaken in one center; therefore, it may not necessarily be possible to extrapolate these results to other regions or ethnic groups. Secondly, the sample size is small and the treatment period short. However, this data will inform a subsequent multi-centered study compromising a sufficient sample size over a longer treatment period.</offsets></p><p id="Par71"><offsets xml_i="34728" xml_f="34993" txt_i="22530" txt_f="22795">In conclusion, this prospective study will demonstrate that the JDTLG with conventional treatment is able to effectively and safely treat PSD with qi deficiency and blood stasis syndrome, thereby providing a new direction for treating PSD with minimal side effects.</offsets></p><sec id="Sec23"><title><offsets xml_i="35020" xml_f="35032" txt_i="22796" txt_f="22808">Trial status</offsets></title><p id="Par72"><offsets xml_i="35054" xml_f="35133" txt_i="22809" txt_f="22888">The trial was initiated in April 2017 and is currently recruiting participants.</offsets></p></sec></sec><sec sec-type="supplementary-material"><title><offsets xml_i="35195" xml_f="35210" txt_i="22891" txt_f="22906">Additional file</offsets></title><sec id="Sec24"><p><offsets xml_i="35237" xml_f="35238" txt_i="22907" txt_f="22908">
</offsets><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13063_2018_2633_MOESM1_ESM.pdf"><label><offsets xml_i="35358" xml_f="35376" txt_i="22908" txt_f="22926">Additional file 1:</offsets></label><caption><p><offsets xml_i="35396" xml_f="35426" txt_i="22926" txt_f="22956">SPIRIT Checklist. (PDF 211 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="35473" xml_f="35474" txt_i="22957" txt_f="22958">
</offsets></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AEs</term><def><p id="Par5">Adverse events</p></def></def-item><def-item><term>BI</term><def><p id="Par6">Barthel Index</p></def></def-item><def-item><term>CDMS</term><def><p id="Par7">Clinical data management system</p></def></def-item><def-item><term>CRF</term><def><p id="Par8">Case report form</p></def></def-item><def-item><term>CT</term><def><p id="Par9">Computed tomography</p></def></def-item><def-item><term>ECG</term><def><p id="Par10">Electrocardiogram</p></def></def-item><def-item><term>HAMD-17</term><def><p id="Par11">17-item Hamilton Depression Scale</p></def></def-item><def-item><term>IL</term><def><p id="Par12">Interleukin</p></def></def-item><def-item><term>MRI</term><def><p id="Par13">Magnetic resonance imaging</p></def></def-item><def-item><term>NIHSS</term><def><p id="Par14">National Institute of Health Stroke Scale</p></def></def-item><def-item><term>PSD</term><def><p id="Par15">Post-stroke depression</p></def></def-item><def-item><term>SNRI</term><def><p id="Par16">Serotonin and norepinephrine reuptake inhibitors</p></def></def-item><def-item><term>SSRI</term><def><p id="Par17">Selective serotonin reuptake inhibitors</p></def></def-item><def-item><term>TCM</term><def><p id="Par18">Traditional Chinese medicine</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s13063-018-2633-4) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We appreciate the effort of all the researchers for participating in this trial, recruiting and treating participants.</p><sec id="FPar1"><title>Funding</title><p id="Par73">This trial was supported financially by China’s Ministry of Science and Technology major new drug creation project (Number 2012ZX09103201–015) and the National Basic Research Program (973 program) (Number 2015CB554405). The funding parties will play no role in the study design, study conduct, results, or dissemination.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par74">The datasets generated during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Dissemination policy</title><p id="Par75">Results will be published in peer-reviewed journals and presented at national and international scientific meetings regardless of the magnitude or direction of effect.</p></sec></ack><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>JXL, LJM, LX, and JGR were responsible for the design, the supervision of the study. AMZ drafted the manuscript, WRQ, MJY, KB, and DC participated in the revision of the manuscript and coordination of the study. All authors read and approved the final manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar4"><title>Ethics approval and consent to participate</title><p id="Par76">The trial will be conducted according to the principles of the Declaration of Helsinki (2000 version). Trial organization, data management, monitoring and reporting of the study will also be performed in accordance with the guidelines for Good Clinical Practice (2003 version) and other regulations. The final protocol (version:1.1, 10 December, 2016) and the consent form have been reviewed and approved by the Ethics Committee of Xiyuan Hospital of China Academy of Chinese Medical Sciences (approval number: 2016XLA158-2). Approval will be sought from the Ethics Committee for all protocol amendments prior to dissemination to recruitment site. The trial is registered at ClinicalTrials.gov (NCT03147053). Each participant will receive a Participant Information Sheet which will be explained thoroughly by the investigator, including potential benefits and risks. The principal investigator or their delegated representative will obtain written informed consent from the patient or their legal authorized representative before allocated to a treatment group. In accordance with ethical guidelines, the anonymity, confidentiality, and privacy of participants will be protected. The electronic clinical trial management data system and all electronic data will be password protected. All publication material will refer to general trial results as aggregate data and no individual participant names or identifying information will be released.</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par77">We have gained informed consent for publication of the dataset from patients at the point of recruitment to the trial. All the patient details will be fully anonymous.</p></sec><sec id="FPar6"><title>Competing interests</title><p id="Par78">The authors declare that they have no competing interests.</p></sec><sec id="FPar7"><title>Publisher’s Note</title><p id="Par79">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>RG</given-names></name><name><surname>Jorge</surname><given-names>RE</given-names></name></person-group><article-title>Post-stroke depression: a review</article-title><source>Am J Psychiatr</source><year>2015</year><volume>173</volume><issue>3</issue><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2015.15030363</pub-id><pub-id pub-id-type="pmid">26684921</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenzi</surname><given-names>GL</given-names></name><name><surname>Altieri</surname><given-names>M</given-names></name><name><surname>Maestrini</surname><given-names>I</given-names></name></person-group><article-title>Post-stroke depression</article-title><source>Rev Neurol</source><year>2008</year><volume>164</volume><issue>10</issue><fpage>837</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1016/j.neurol.2008.07.010</pub-id><pub-id pub-id-type="pmid">18771785</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackett</surname><given-names>ML</given-names></name><name><surname>Köhler</surname><given-names>S</given-names></name><name><surname>O’Brien</surname><given-names>JT</given-names></name><etal></etal></person-group><article-title>Neuropsychiatric outcomes of stroke</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><issue>5</issue><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70016-X</pub-id><pub-id pub-id-type="pmid">24685278</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackett</surname><given-names>ML</given-names></name><name><surname>Pickles</surname><given-names>K</given-names></name></person-group><article-title>Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies</article-title><source>Int J Stroke</source><year>2014</year><volume>9</volume><issue>8</issue><fpage>1017</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1111/ijs.12357</pub-id><pub-id pub-id-type="pmid">25117911</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayerbe</surname><given-names>L</given-names></name><name><surname>Ayis</surname><given-names>S</given-names></name><name><surname>Wolfe</surname><given-names>CDA</given-names></name><etal></etal></person-group><article-title>Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis</article-title><source>Br J Psychiatry</source><year>2013</year><volume>202</volume><issue>1</issue><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.111.107664</pub-id><pub-id pub-id-type="pmid">23284148</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutlubaev</surname><given-names>MA</given-names></name><name><surname>Hackett</surname><given-names>ML</given-names></name></person-group><article-title>Part II: predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies</article-title><source>Int J Stroke</source><year>2014</year><volume>9</volume><issue>8</issue><fpage>1026</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1111/ijs.12356</pub-id><pub-id pub-id-type="pmid">25156411</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli</surname><given-names>F</given-names></name><name><surname>Lillia</surname><given-names>N</given-names></name><name><surname>Lax</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Depression after stroke and risk of mortality: a systematic review and meta-analysis</article-title><source>Stroke Res Treat</source><year>2013</year><volume>2013</volume><fpage>862978</fpage><pub-id pub-id-type="pmid">23533964</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Deng L, Sun X, Qiu S, et al. Interventions for management of post-stroke depression: A Bayesian network meta-analysis of 23 randomized controlled trials. Sci Rep. 2017;7(1). 10.1038/s41598-017-16663-0.</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Libr. 2008; 10.1002/14651858.CD003437.pub3.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coupland</surname><given-names>C</given-names></name><name><surname>Dhiman</surname><given-names>P</given-names></name><name><surname>Morriss</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Antidepressant use and risk of adverse outcomes in older people: population based cohort study</article-title><source>BMJ</source><year>2011</year><volume>343</volume><fpage>d4551</fpage><pub-id pub-id-type="doi">10.1136/bmj.d4551</pub-id><pub-id pub-id-type="pmid">21810886</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Zeng LF, Cao Y, Wang L, et al. Role of medicinal plants for Liver-Qi regulation adjuvant therapy in post-stroke depression: a systematic review of literature. Phytother Res. 2016; 10.1002/ptr.5740.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Meng F, Hou S, Yuan D, et al. Modern literature review of syndrome differentiation of ischemic stroke. Liaoning J Trad Chin Med. 2014;(2):207–10. [Article in Chinese]. 10.13192/j.issn.1000-1719.2014.02.005.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>H-L</given-names></name></person-group><article-title>Data mining and analysis of Professor Yujie Liu's experience in treating post-stroke depression-based on TCM Inheritance Assisted System</article-title><source>Method Mod Distance Educ Tradit Chin Med</source><year>2016</year><volume>14</volume><issue>3</issue><fpage>52</fpage><lpage>58</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>SJ</given-names></name><name><surname>Hu</surname><given-names>G-J</given-names></name></person-group><article-title>Observation on curative effect of <italic>Yiqi Huoxue Jieyu</italic> Decoction on post-stroke depression</article-title><source>J Anhui Univ Chin Med</source><year>2017</year><volume>36</volume><issue>3</issue><fpage>12</fpage><lpage>15</lpage></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Song WT, Xu L, Ren JX, et al. Effect <italic>of Jiedu Tongluo</italic> Capsule on Qi-relieving depression in rats with depression after stroke. World Sci Technol. 2015;(7):1380–5. [Article in Chinese]. <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&amp;dbname=CJFDLAST2015&amp;filename=SJKX201507012&amp;v=MTI0NzdyL0xOaWZBZHJHNEg5VE1xSTlFWm9SOGVYMUx1eFlTN0RoMVQzcVRyV00xRnJDVVJMS2ZZK1JwRmlEaFc=">http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&amp;dbname=CJFDLAST2015&amp;filename=SJKX201507012&amp;v=MTI0NzdyL0xOaWZBZHJHNEg5VE1xSTlFWm9SOGVYMUx1eFlTN0RoMVQzcVRyV00xRnJDVVJMS2ZZK1JwRmlEaFc=</ext-link>.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Wei-Yi O, Tahira F, Hwee-Ling K, et al. Protective effects of ginseng on neurological disorders. Frontiers in Aging Neuroscience, 2015;7:129. 10.3389/fnagi.2015.00129. </mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>The antidepressant effects and mechanism of action of total saponins from the caudexes and leaves of <italic>Panax notoginseng</italic> in animal models of depression</article-title><source>Phytomedicine</source><year>2011</year><volume>18</volume><issue>8</issue><fpage>731</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2010.11.014</pub-id><pub-id pub-id-type="pmid">21273053</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>R</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title>Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window</article-title><source>Neurotherapeutics</source><year>2011</year><volume>8</volume><issue>3</issue><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1007/s13311-011-0051-3</pub-id><pub-id pub-id-type="pmid">21647765</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar Singh</surname><given-names>S</given-names></name><name><surname>Barreto</surname><given-names>GE</given-names></name><name><surname>Aliev</surname><given-names>G</given-names></name><etal></etal></person-group><article-title><italic>Ginkgo biloba</italic> as an alternative medicine in the treatment of anxiety in dementia and other psychiatric disorders</article-title><source>Curr Drug Metab</source><year>2017</year><volume>18</volume><issue>2</issue><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.2174/1389200217666161201112206</pub-id><pub-id pub-id-type="pmid">27908257</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulsulkar</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>ZA</given-names></name></person-group><article-title><italic>Ginkgo biloba</italic> prevents transient global ischemia-induced delayed hippocampal neuronal death through antioxidant and anti-inflammatory mechanism</article-title><source>Neurochem Int</source><year>2013</year><volume>62</volume><issue>2</issue><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2012.11.017</pub-id><pub-id pub-id-type="pmid">23228346</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus</article-title><source>Br J Pharmacol</source><year>2012</year><volume>166</volume><issue>6</issue><fpage>1872</fpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.01902.x</pub-id><pub-id pub-id-type="pmid">22335772</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Aboukhatwa</surname><given-names>MA</given-names></name><name><surname>Lei</surname><given-names>DL</given-names></name><etal></etal></person-group><article-title>Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice</article-title><source>Neuropharmacology</source><year>2010</year><volume>58</volume><issue>6</issue><fpage>911</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.11.002</pub-id><pub-id pub-id-type="pmid">19917299</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Wang Xin-de. All kinds of cerebrovascular disease diagnosis points. Chin J Neurol, 1996;379–380. [Article in Chinese].</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="editor"><collab>Chinese Medical Association psychiatric branch</collab></person-group><source>Classification and Diagnostic Criteria for Mental Disorders in China</source><year>2001</year><edition>3</edition><publisher-loc>Jinan</publisher-loc><publisher-name>Shandong Science and Technology Press</publisher-name><fpage>87</fpage><lpage>88</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>XY</given-names></name></person-group><source>Guidelines for clinical research of new Chinese medicine</source><year>2002</year><publisher-loc>Beijing</publisher-loc><publisher-name>China Medical Science Press</publisher-name></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group><article-title>A rating scale for depression</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1960</year><volume>23</volume><issue>1</issue><fpage>56</fpage><pub-id pub-id-type="doi">10.1136/jnnp.23.1.56</pub-id><pub-id pub-id-type="pmid">14399272</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brott</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>HP</given-names></name><name><surname>Olinger</surname><given-names>CP</given-names></name><etal></etal></person-group><article-title>Measurements of acute cerebral infarction: a clinical examination scale</article-title><source>Stroke</source><year>1989</year><volume>20</volume><issue>7</issue><fpage>864</fpage><pub-id pub-id-type="doi">10.1161/01.STR.20.7.864</pub-id><pub-id pub-id-type="pmid">2749846</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>RF</given-names></name></person-group><article-title>Interobserver agreement for the assessment of handicap in stroke patients</article-title><source>Stroke</source><year>1988</year><volume>19</volume><issue>5</issue><fpage>604</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1161/01.STR.19.5.604</pub-id><pub-id pub-id-type="pmid">3363593</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>FJ</given-names></name><name><surname>Barthel</surname><given-names>DW</given-names></name></person-group><article-title>Functional evaluation: the Barhel Index[J]</article-title><source>Md Med J</source><year>1965</year><volume>14</volume><issue>14</issue><fpage>61</fpage></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">State Administration of Traditional Chinese Medicine. Criatia of diagnosis and therapeutic effect of disease and syndromes in traditional Chinese medicine [M]: Nanjing University Press; 1994. [Book in Chinese].</mixed-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Bae</surname><given-names>KY</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><etal></etal></person-group><article-title>Effects of interleukin-6, interleukin-18, and statin use, evaluated at acute stroke, on post-stroke depression during 1-year follow-up</article-title><source>Psychoneuroendocrinology</source><year>2016</year><volume>72</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2016.07.001</pub-id><pub-id pub-id-type="pmid">27428088</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahramabadi</surname><given-names>R</given-names></name><name><surname>Fathollahi</surname><given-names>MS</given-names></name><name><surname>Hashemi</surname><given-names>SM</given-names></name><etal></etal></person-group><article-title>Serum levels of IL-6, IL-8, TNF-α, and TGF-β in chronic HBV-infected patients: effect of depression and anxiety</article-title><source>Lab Med</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>3757</fpage></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towfighi</surname><given-names>A</given-names></name><name><surname>Ovbiagele</surname><given-names>B</given-names></name><name><surname>El Husseini</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Post stroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2017</year><volume>48</volume><issue>2</issue><fpage>e30</fpage><lpage>e43</lpage><pub-id pub-id-type="doi">10.1161/STR.0000000000000113</pub-id><pub-id pub-id-type="pmid">27932603</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2017. 10.1016/j.pharmthera.2017.11.005.</mixed-citation></ref></ref-list></back></article>